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Fenugreek Counters the Effects of 
High Fat Diet on Gut Microbiota in 
Mice: Links to Metabolic Benefit
Annadora J. Bruce-Keller1*, Allison J. Richard1, Sun-ok fernandez-Kim1, David M. Ribnicky2, 
J. Michael Salbaum1, Susan newman1, Richard carmouche1 & Jacqueline M. Stephens1
fenugreek (Trigonella foenum-graecum) is an annual herbaceous plant and a staple of traditional health 
remedies for metabolic conditions including high cholesterol and diabetes. While the mechanisms 
of the beneficial actions of fenugreek remain unknown, a role for intestinal microbiota in metabolic 
homeostasis is likely. To determine if fenugreek utilizes intestinal bacteria to offset the adverse 
effects of high fat diets, C57BL/6J mice were fed control/low fat (CD) or high fat (HFD) diets each 
supplemented with or without 2% (w/w) fenugreek for 16 weeks. The effects of fenugreek and HFD on 
gut microbiota were comprehensively mapped and then statistically assessed in relation to effects on 
metrics of body weight, hyperlipidemia, and glucose tolerance. 16S metagenomic analyses revealed 
robust and significant effects of fenugreek on gut microbiota, with alterations in both alpha and beta 
diversity as well as taxonomic redistribution under both CD and HFD conditions. As previously reported, 
fenugreek attenuated HFD-induced hyperlipidemia and stabilized glucose tolerance without affecting 
body weight. Finally, fenugreek specifically reversed the dysbiotic effects of HFD on numerous taxa 
in a manner tightly correlated with overall metabolic function. Collectively, these data reinforce the 
essential link between gut microbiota and metabolic syndrome and suggest that the preservation 
of healthy populations of gut microbiota participates in the beneficial properties of fenugreek in the 
context of modern Western-style diets.
Obesity linked to Western-style diets is the prototypical ailment of the modern era. Obesity currently affects more 
than 35% of Americans1; and in addition to ties with type 2 diabetes and cardiovascular disease, obesity increases 
the risk of all-cause mortality and exacerbates anxiety and depression2–5. While search for effective obesity treat-
ments has become a priority in biomedical research, available pharmacological options for obesity are under-
mined by issues related to toxicity and off-target side6. Herbal medicine or phytotherapy has long been a source 
of traditional medicinal remedies, and indeed, interest in generally regarded as safe (GRAS) plant materials for 
the clinical treatment of obesity is growing (reviewed in7,8). Fenugreek (Trigonella foenum-graecum) is an annual 
herbaceous plant and a staple of traditional health remedies to treat hyperlipidemia and diabetes9–12, as well as 
mood disorders13. Laboratory studies demonstrate protective effects of fenugreek on diabetes14–18, and suggest 
that potential mechanisms might include inhibition of intestinal glucose absorption14–16, delayed gastric empty-
ing15, and/or insulinotropic activity19,20,17,18. Protective effects of fenugreek on cholesterol and hyperlipidemia21 
might be based on modulation of hepatic steatosis22–26, inflammation26–28, and/or oxidative stress secondary to 
diabetes29–32. While the exact mechanisms whereby fenugreek or its constituents confers metabolic resiliency are 
unknown, data show that fenugreek administration can also modulate intestinal microbiota, which can in turn 
impact metabolic physiology33,34.
A remarkably mutualistic relationship exists between gut microbiota and their mammalian hosts, with micro-
biota providing protection against ingested pathogens, neutralizing carcinogens, and metabolizing otherwise 
inaccessible lipids and polysaccharides into potent bioactive metabolites35. Sequencing data show that mod-
ern high fat/calorie diets can disrupt gut microbiota, reducing bacterial diversity and upsetting the balance of 
pathogenic and commensal bacteria36. Data from our lab and others show that such diet-induced gut dysbiosis 
is sufficient to impair both metabolic and neurologic function37,38, suggesting that preservation of healthy gut 
microbiota could offset the pathophysiologic effects of high fat diets39. As fenugreek has indeed been shown 
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to modulate intestinal bacteria in several models33,34,40, studies were designed to determine if fenugreek could 
offset the effects of a high fat diet on gut dysbiosis, and to establish the relationship of fenugreek-shaped gut 
microbiota to clinically relevant metrics of metabolic function. To this end, data from our previously published 
study on the effects of fenugreek on mice given a high fat diet were extended to include sequencing and statistical 
assessment of gut microbiota. As reported in our previous study, high fat or nutritionally matched low fat diets 
supplemented with ground fenugreek seeds (2% w/w) were administered to male C57BL/6J mice for 16 weeks, 
and the metabolic effects of the various diets on adiposity, glycemic control, and hyperlipidemia were quantified41. 
Metagenomic sequencing of fecal microbiota collected from mice was conducted, and diet-related changes in gut 
microbiota were statistically analyzed in relation to established metrics of metabolic function.
Results
Fenugreek improves glucose tolerance and dyslipidemia in mice given high fat diet. Data in 
this manuscript is built on initial publication of the effects of whole fenugreek seed supplementation (2% w/w) 
on overall metabolic function in the context of a 16-week trial of high fat diet consumption41, and thus previously 
published data are only summarized in this report. Briefly, data show that fenugreek supplementation increased 
HDL and decreased LDL cholesterol levels in high fat fed-mice (Table 1). Furthermore, fenugreek significantly 
improved glucose tolerance (as measured 40 minutes after oral glucose loading), but did not affect HFD-induced 
changes in total cholesterol, body weight, amount of body fat, or fasting blood glucose (Table 1). Fenugreek 
administration did not cause changes in food intake41.
Fenugreek and high fat diet exert pronounced effects on gut microbial composition. The 
impact of fenugreek on intestinal microbiota was determined by 16S sequencing of fecal samples isolated from 
mice at euthanasia as described in Methods. Initial weighted and unweighted Unifrac phylogenetic analyses 
reveal that the microbiomes of fenugreek-fed mice were significantly different from non-fenugreek mice under 
both control diet and high fat-fed conditions (Table 2). Indeed, the magnitude of the effects of fenugreek were 
similar in that of the high fat dies as compared to control diet (Table 2). These robust shifts in beta-diversity were 
also apparent on principal component analysis plots generated from normalized read count data (Fig. 1). Finally, 
CD CD/FG HFD HFD/FG
Total Cholesterol 
(mg/dl) 148.9 ± 45.7 136.2 ± 31.7 255.4 ± 32.9*** 245.7 ± 26.3
LDL Cholesterol 
(mg/dl) 9.62 ± 2.6 8.48 ± 2.1 17.98 ± 4.7*** 13.83 ± 4.3
#
HDL Cholesterol 
(%TC) 45.15 ± 12.7 44.86 ± 5.8 28.28 ± 3.3*** 33.3 ± 5.1
#
Body Weight (gr) 31.78 ± 3.2 31.57 ± 2.6 48.73 ± 2.7*** 50.03 ± 2.2
Body Fat (gr) 5.15 ± 1.8 5.04 ± 1.2 16.61 ± 1.3*** 16.86 ± 1.3
Fasting Blood 
Glucose (mg/dl) 153.4 ± 16.8 149.4 ± 23.4 211.1 ± 16.8*** 219.1 ± 21.1
Glucose Tolerance 
(40 min) 234.0 ± 49.3 213.5 ± 23.3 386.1 ± 89.9*** 311.6 ± 75.8
#
Table 1. Summary of fenugreek-induced metabolic resiliency: decreased hyperlipidemia and improved glucose 
tolerance. Adult male C57Bl/6 mice were given high fat (HFD) or nutritionally matched control diet (CD) with 
or without fenugreek (FG; 2% w/w), and subject to measures of metabolic function as described in Methods. 
Statistically significant differences in metabolic parameters in HFD-fed mice as compared to CD-fed mice are 
mice are noted by ***(p < 0.001), while significant changes in mice given HFD/FG as compared to HFD-fed 
mice are noted by #(p < 0.05). Adapted from previously published data41.
Comparison Score P value
Weighted Unifrac
CD vs CD/FG 0.65012 <0.001***
HFD vs HFD/
FG 0.61915 <0.001***
CD vs HFD 0.796987 <0.001***
Unweighted Unifrac
CD vs CD/FG 0.90777 <0.001***
HFD vs HFD/
FG 0.885073 0.002009**
CD vs HFD 0.952579 0.001009**
Table 2. Differences in microbiota community composition in mice with CD- and HFD-shaped microbiota 
with and without fenugreek. Operational taxonomical units (OTU) were identified based on sequence 
clustering as described in Methods, and generation of a read count table was performed with the software 
package ‘usearch’. Statistical tests for differential representation were performed with tools incorporated in 
‘mothur’, and statistically significant differences in microbiota community composition between groups were 
detected using both weighted and unweighted Unifrac phylogenetic analysis tools.
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data show that fenugreek also significantly increased alpha diversity (Shannon metrics) in both control diet and 
high fat-fed mice (Fig. 2).
Fenugreek can correct the dysbiotic effects of high fat diet on intestinal microbial popu-
lations. To assess the impact of fenugreek and HFD on gut microbial composition in greater statistical 
detail, a differential analysis of count data was conducted using DESeq. 2. Specifically, the specific individual 
operational taxonomic units (OTUs) whose relative representation was significantly (p < 0.05 adjusted with 
Benjamini-Hochberg correction) changed by high fat diet were identified using DESeq. 2. These analyses revealed 
that out of 410 Core OTUs (identified in all mice), the relative representation of 147 individual OTUs was sig-
nificantly different in HFD-fed mice as compared to CD-fed mice (Fig. 3); with 57 increased and 90 decreased, 
respectively, by HFD. A similar DESeq. 2 analysis of these 147 “HFD-transformed” taxa was conducted to identify 
those that were significantly affected by fenugreek such that the direction of the change induced by high fat diet 
was reversed. This ivvestigation of “fenugreek-corrected” taxa revealed that fenugreek corrected the effects of 
HFD on 50 of these OTUs by reducing the representation of 27 HFD-increased OTUs and augmenting the rep-
resentation of 23 OTUs reduced by HFD (Fig. 3). These analyses reflect the robust effect of both fenugreek and 
HFD on gut microbiota, and show that fenugreek is able to significantly correct much (greater than 34%) of the 
dysbiotic effects of HFD.
Representation of Fenugreek-corrected taxa largely predicts overall metabolic function. In 
the final set of analyses, the 50 fenugreek-corrected taxa whose representation was skewed in one direction by 
HFD but in the opposite direction by fenugreek was examined in relation to metabolic function. Specifically, to 
determine if the relative representation of fenugreek-corrected taxa could be used to predict metabolic resiliency, 
the statistical relationship of fenugreek-corrected taxa representation to the metrics of metabolic function listed in 
Table 1 was determined. To this end, a matrix was built containing OTU count data for all 50 fenugreek-corrected 
Figure 1. Fenugreek changes intestinal microbial populations in mice. Fecal microbiome populations from CD, 
CD/FG, HFD, and HFD/FG mice were analyzed using 16S rRNA sequencing, and multi-dimensional scaled 
principal coordinate analysis were used to visualize UniFrac distances of fecal samples from individual recipient 
mice. Samples from CD, CD/FG, HFD, and HFD/FG mice are depicted as blue, purple, red, and green symbols, 
respectively.
Figure 2. Fenugreek increases overall intestinal microbial diversity. Fecal microbiome populations from CD, 
CD/FG, HFD, and HFD/FG mice were analyzed using 16S rRNA sequencing, and box plots were generated to 
depict differences in Shannon α-diversity. Data show that mice supplemented with 2% fenugreek in their feed 
exhibited a statistically significant (**p < 0.01) increase in α-diversity compared to mice given CD or HFD 
alone.
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taxa along with all metabolic data depicted in Table 1, including those indices not affected by fenugreek. Pairwise 
Pearson correlations indicate that the relative expression of many of these 50 OTUs were highly predictive of met-
abolic function. For example, of the 23 taxa decreased by HFD but increased with fenugreek supplementation, 8 
taxa (all in the fermicutes phylum) significantly correlated with at least 1 metric of metabolic function (Table 3, 
see Supplementary Table 1 for additional details (log2FC and Pearson r values) on HFD-decreased, fenugreek 
corrected taxa). Likewise, of the 27 taxa increased by HFD but decreased with fenugreek supplementation, 20 
taxa significantly correlated with selected metrics of metabolic function (Table 4, see Supplementary Table 2 for 
additional details (log2FC and Pearson r values) on HFD-increased, fenugreek corrected taxa). It is important 
to note that the representation of fenugreek-corrected taxa correlated frequently with aspects of metabolic func-
tion (e.g., body weight, body fat, total cholesterol, fasting blood glucose) that were not significantly improved in 
fenugreek-treated mice.
Discussion
While beneficial effects of fenugreek on hyperlipidemia and hyperglycemia have been widely reported, the mech-
anisms of fenugreek-mediated actions on metabolic function are unknown. Here we demonstrate the robust 
effects of fenugreek on gut microbiota, and describe a novel combination of statistical analyses including Unifrac, 
iterative DESeq. 2, and pairwise correlation matrices to generate insight into the role of intestinal microbial 
changes in the protective effects of fenugreek. Specifically, sequencing analyses reveal that fenugreek significantly 
increased overall microbiome diversity in mice, and specifically reversed the actions of high dietary fat on key 
intestinal taxa. Furthermore, the representation of fenugreek-corrected taxa significantly correlated with meta-
bolic function, including changes in body weight and composition, glucose regulation, and hyperlipidemia.These 
findings are in agreement with the extensive body of literature documenting the ability of high fat diet to reduce 
bacterial diversity and disrupt the balance of pathogenic/commensal bacteria within the intestine36,42,38,43. As data 
from our lab and others show that this pattern of gut dysbiosis is sufficient to impair both metabolic and neuro-
logic function37,44–48, data in this paper suggest that the reported effects of fenugreek on gut microbiota33,34,40,49, 
may be fundamental to its beneficial properties. In light of the stubborn prevalence of obesity and the pervasive 
accessibility of unhealthy diets, it is both clinically significant and generally promising that these data suggest 
that partial reversal of gut dysbiosis and metabolic impairment can be achieved with botanical supplementation 
within the context of unhealthy, Western-style diets.
While the association of intestinal dysbiosis with metabolic disease is well established45–48 causal relationships 
have not been identified and it is not understood how microbiome constituents impact metabolic resilience/vul-
nerability. Three major phyla are the most abundant in the human distal intestine: Bacteroidetes (gram-negative), 
Firmicutes (gram-positive), and Actinobacteria (gram-positive). Early studies suggested that obesity causes 
reductions in Bacteroidetes and increases in Firmicutes38,43 and indeed further studies indicate that these changes 
are reversed with weight loss50,51. While these data suggest that the balance between these phyla might broadly 
impact host physiology, this binary distinction does not always occur52,53 and may be too simple to faithfully 
reflect the complexity of diet-induced changes to the gut microbiome54–56. In the present study as well as our 
previous studies54,57, differences between control and high fat groups did not manifest as phylum-level shifts 
but rather differential representation within taxa, particularly Firmicutes. Indeed, the majority of taxa included 
in Tables 3 and 4 arise from the Clostridium class (Clostridium cluster XIVa) or the Clostridium leptum group 
(Clostridium cluster IV). This is notable, as divergent shifts in the representation of Clostridia have been reported 
in other pathophysiological conditions. For example, while overall Clostridium representation generally increases 
with age, Clostridium XIVa clusters have been shown to be significantly reduced in the elderly58. The bacteria 
in Clostridium XIVa play major roles in the fermentation of carbohydrates within the gut59, and the major end 
products of hind-gut fermentation are short-chain fatty acids (SCFAs). Further, Fermicutes produce primarily 
butyrate as their metabolic end product60, and butyrate is the main source of nutrition for gut epithelium cells61. 
Depletion of butyrate is associated with impaired intestinal barrier integrity62, and loss of intestinal barrier func-
tion is in turn associated with a growing number of inflammatory disease states diseases, including obesity as well 
as autoimmune diseases and cancer (reviewed in63,64). While butyrate was not directly measured in the present 
Figure 3. Graphical representation of fenugreek’s ability to reverse HFD-induced changes in individual 
intestinal microbiota. The ability of high fat diet to significantly alter the representation of individual taxa was 
assessed as described in Methods showing that out of 410 Core OTUs, 57 were significantly increased and 90 
significantly decreased by HFD. Fenugreek supplementation significantly reversed the effects of HFD on 50 of 
these OTUs by reducing the representation of 27 HFD-increased OTUs and bolstering the representation of 23 
OTUs reduced by HFD.
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study, decreased levels of butyrate and other SCFA are widely reported in the context of obesity while high-fiber 
plant products are known to increase colonic fermentation and the generation of SCFA65.
Our data indicate that fenugreek is particularly effective against hyperlipidemia, which is in keeping with 
results of both experimental and clinical studies14,22,30,66. While there are several mechanisms whereby changes 
in gut microbiota could mediate the effects of fenugreek on serum lipids, most ultimately impact the absorp-
tion of dietary fat. For example, intestinal microbiota alter the metabolism of diet-derived long-chain fatty acids 
such as conjugated linoleic acid, modulating absorption67. Gut microbiota can also moderate cholesterolemia 
Correlation (Pearson) of HFD-Decreased, Fenugreek-Corrected OTU’s to Metrics of Metabolic Function











Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species1 ns ns ns ns 0.0014 ns 0.0001
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species2 ns ns ns 0.0027 0.0025 ns ns
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species3 0.0001 0.0034 0.0011 ns ns 0.0006 0.0001
Firmicutes/Clostridia/Clostridiales/Ruminococcaceae/Flavonifractor 1.2E-05 0.0005 0.0001 1.6E-06 2.1E-06 2.2E-05 1.9E-05
Firmicutes/Erysipelotrichia/Erysipelotrichales/Erysipelotrichaceae/Turicibacter 0.0004 ns 0.0024 ns ns ns 0.0015
Firmicutes/Clostridia/Clostridiales/Ruminococcaceae/Oscillibacter 0.0002 ns 1.3E-05 ns 4.0E-05 0.0002 4.2E-05
Firmicutes/Clostridia/Clostridiales/Ruminococcaceae/Intestinimonas 0.0009 0.0021 0.0026 ns ns 0.0004 0.0017
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Acetatifactor/Species 1 ns ns ns ns ns ns 0.0012
Table 3. OTUs that predicts metabolic decline in high fat-fed mice. Individual OTUs in which fenugreek 
administration reversed high fat diet-induced decreases in representation were correlated against measures of 
hyperlipidemia. Data are p values of Pearson correlation with total cholesterol (mg/dl), low-density lipoprotein 
(LDL Chol.; mg/dl), high-density lipoprotein (HDL Chol.; %TC), body weight (grams), body fat (grams), 
fasting blood glucose (mg/dl), and glucose tolerance (blood glucose levels 40 minutes after oral loading). See 
Supplementary Table 1 for additional details (log2FC and Pearson r values) on HFD-decreased, fenugreek 
corrected taxa.
Correlation (Pearson) of HFD-Increased, Fenugreek-Corrected OTU’s to Metrics of Metabolic Function













Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 4 ns 4.9E-05 ns ns ns ns ns
Firmicutes/ClostridiaClostridiales/Ruminococcaceae/Anaerotruncus 0.0004 1.3E-08 ns ns 0.0016 ns 4.6E-06
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 5 ns 5.8E-05 0.0024 ns ns ns ns
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 6 0.0002 4.9E-09 0.0051 ns ns ns 0.0002
Bacteroidetes/Bacteroidia/Bacteroidales/Porphyromonadaceae/Barnesiella/Species 1 9.1E-05 4.1E-10 ns 0.0009 0.0009 0.0024 1.6E-06
Bacteroidetes/Bacteroidia/Bacteroidales/Porphyromonadaceae/Barnesiella/Species 2 0.0005 4.2E-09 ns ns ns ns 8.8E-06
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 7 8.1E-07 5.7E-10 4.8E-05 ns ns ns 0.0001
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 8 0.0001 0.0002 0.0030 ns 1.2E-05 0.0011 1.3E-05
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 9 4.1E-06 5.9E-08 0.0007 ns 1.2E-06 4.1E05 ns
Firmicutes/Bacilli/Lactobacillales/Streptococcaceae/Streptococcus ns ns ns ns ns ns 0.0007
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 10 0.0009 2.1E-05 ns ns 0.0002 ns 5.0E-06
Firmicutes/Bacilli/Lactobacillales/Lactobacillaceae/Lactobacillus/Species 1 4.2E-06 ns ns 7.1E-08 4.3E-09 5.6E07 1.1E-06
Firmicutes/Bacilli/Lactobacillales/Lactobacillaceae/Lactobacillus/Species 2 1.3E-06 0.0001 ns 2.9E-08 2.1E-09 2.9E-07 5.2E-07
Actinobacteria/Actinobacteria/Coriobacteridae/Coriobacteriales/Coriobacterineae ns ns ns ns ns ns 0.0033
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Roseburia 6.0E-05 5.4E-07 0.0004 ns ns ns ns
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 11 ns ns ns 0.0030 0.0016 ns 0.0015
Firmicutes/Clostridia/Clostridiales/Clostridiales_Incertae_Sedis_XI/Dethiosulfatibacter 0.0039 ns ns 0.0004 ns ns
Bacteroidetes/Bacteroidia/Bacteroidales/Porphyromonadaceae/Barnesiella/Species 3 ns 1.4E-05 ns ns ns ns 0.0040
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Acetatifactor/Species 2 0.0003 0.0002 ns ns 1.6E-05 ns ns
Firmicutes/Clostridia/Clostridiales/Lachnospiraceae/Clostridium_XlVa/Species 12 5.2E-05 2.2E-07 0.0003 ns ns ns ns
Table 4. OTUs that predicts metabolic decline in high fat-fed mice. Individual OTUs in which fenugreek 
administration reversed high fat diet-induced increases in representation were correlated against measures of 
hyperlipidemia. Data are correlation coefficients (Pearson r) and p values of correlation with total cholesterol 
(mg/dl), low-density lipoprotein (LDL Chol.; mg/dl), high-density lipoprotein (HDL Chol.; %TC), body weight 
(grams), body fat (grams), fasting blood glucose (mg/dl), and glucose tolerance (blood glucose levels 40 minutes 
after oral loading). See Supplementary Table 2 for additional details (log2FC and Pearson r values) on HFD-
increased, fenugreek corrected taxa.
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by regulating cholesterol conversion into coprostanol68. Dietary cholesterol is largely incorporated into chylo-
microns for absorption in the small intestine. However, significant quantities of cholesterol (as much as 1 gram 
per day) escape proximal absorption to enter the colon to be either be excreted or absorbed. Microbial-based 
metabolism of cholesterol into coprostanone/coprostanol reduces blood cholesterol by increasing fecal choles-
terol excretion69,70. Interestingly, recent data suggest that taxa arising from Lachnospiraceae and Runinococcacea 
families of the phylum Fermicutes are uniquely associated with high coprostanol generation in healthy humans71, 
while other studies likewise link these gut microbiota to variation in blood lipid levels independently of age, sex, 
and host genetics72. It is important to note that seven of the eight of the taxa listed in Table 3 are members of 
Lachnospiraceae and Runinococcacea families, suggesting that reversal of HFD-induced decreases in these key 
taxa by fenugreek could remediate hyperlipidemia by promoting fecal fat excretion. In further support of this 
scenario, published data suggest that fenugreek supplementation can dose-dependently increase fecal excretion of 
cholesterol from rats given high fat/high calorie diets73. Collectively, these data raise the possibility that increased 
representation of coprostanoligenic taxa arising from Lachnospiraceae and Runinococcacea families could par-
ticipate in the lipid-lowering effects of fenugreek, and further suggest that identification and analysis such strains 
could lead to improved understanding and management of hypocholesteremia.
Transformation and metabolism of bile acids is another key pathway whereby fenugreek-shaped intestinal 
bacteria could impact serum lipids (reviewed in74). Indeed, fenugreek has been reported to inhibit the intestinal 
absorption of primary and secondary bile acids75, and to increase bile acid excretion into feces30. While the bulk of 
bile acids released into the intestine are efficiently absorbed and recycled back to the liver, perhaps 5% of the total 
bile acid pool progresses into the colon. Bile acids reaching the colon are subject to several microbial-mediated 
reactions including transformation into secondary bile acids by dihydroxylation, and deconjugation by bile 
salt hydrolases. While data indicate that bile salt hydrolases are a pervasive microbial adaptation to the human 
gut environment with enrichment in major genera including Bacteroides, Clostridium, Lactobacillus, and 
Eubacterium76, probiotics with bile salt hydrolytic activity can lower serum cholesterol77,78. With regard to more 
broad metabolic benefits, secondary bile acids generated by microbial metabolism are potent ligands of the 
G-protein coupled receptor TGR5, the activation of which triggers release of GLP-1 and insulin, thereby modu-
lating host glucose tolerance and energy expenditure79.
While this study is in keeping with an extensive body of literature on the beneficial effects of fenugreek, the use 
of whole seed supplementation precludes identification of the bioactive constituent(s) mediating changes to gut 
microbiota. Furthermore, only male mice were used, so sex-based differences in the effects of fenugreek or the 
relation of such to metabolic function cannot be resolved. This point is especially significant as female C57BL/6J 
mice are generally considered resistant to diet induced obesity80,81. Notwithstanding these limitations, these data 
indicate that fenugreek supplementation can stabilize metabolic function within the context of high fat consump-
tion. Indeed, fenugreek did not affect food intake or alleviate diet-induced obesity, but rather was able to bolster 
resistance of the obese mice to hyperlipidemia and glucose intolerance. We use the term “metabolic resiliency” to 
describe this ability to preserve, at least in part, a healthy metabolic phenotype in the context of powerful external 
stressors – in this case sustained consumption of a high fat diet and the obese state. This is a significant finding, 
as while the components of a healthy lifestyle are generally well known, numerous societal factors including 
poverty, food deserts, irregular/sedentary work schedules combine to hinder a consistently healthy lifestyle for 
most Americans. Thus, use of fenugreek and/or other strategies to maintain a healthy population of intestinal 
microbes in the context of a high fat diet could foster metabolic resilience even when diets/lifestyles are not opti-
mal. Indeed, while fenugreek conferred protection against hyperlipidemia and glucose intolerance, it is important 
to note that representation of specific fenugreek-corrected taxa correlated frequently with aspects of metabolic 
function (e.g., body weight, body fat, total cholesterol, fasting blood glucose) that were not significantly improved 
in fenugreek-treated mice (see Tables 3 and 4). While correlation does not equal causation, these data clearly 
illustrate the very close relationship of individual microbes and microbial balance with metabolic function, and 
raise the possibility that strategic manipulation of key intestinal taxa could result in a more complete reversal of 
the adverse action of high fat diet. Thus, the action of fenugreek could be possibly optimized by dose, preparation, 
or combination with additional factors (probiotics, etc) to have a greater effect on key microbiota, enhancing 
its beneficial profile. These data also suggest that perhaps intestinal microbial “fingerprints” could be generated 
to estimate vulnerability to metabolic dysfunction and/or the potential for efficacy of metabolic interventions. 
Overall, data in the manuscript strongly suggest that the development of microbially-targeted therapies – both 
primary and adjunctive – that are built upon safe, natural, plant-based products like fenugreek could be used to 
attain significant advancements in public health within the context of contemporary dietary environments.
Materials and Methods
Animals and diets. This study was carried out in strict accordance with PHS/NIH guidelines on the use of 
experimental animals, and all experimental protocols were approved by the Institutional Animal Care and Use 
Committee at Pennington Biomedical Research Center. Data in this manuscript follows an initial publication on 
the effects of whole fenugreek seed supplementation (2% w/w) on overall metabolic function in the context of a 
16-week trial of high fat diet consumption41. As detailed in our initial report41, male, 9 week-old C57BL/6 J mice 
were purchased from Jackson Laboratories, and group-housed (4/cage) under standard conditions with ad libi-
tum access to food/water. After 7 days acclimation, mice were randomly separated into the following 4 groups (20 
mice each in each group): high fat diet ± fenugreek (HFD and HFD/FG) and control diet ± fenugreek (CD and 
CD/FG) for 16 weeks. HFD and HFD/FG mice were fed a diet with 60% kcal from fat without or with 2% fenu-
greek seed powder incorporated into the diets, respectively (Research Diets Inc. D12492, D16020410), while CD 
mice were fed a nutritionally matched control low fat diet (10% kcal from fat) with or without 2% fenugreek seed 
powder (Research Diet Inc.; D12450J, D16020408). All diets contained 10% kcal from protein with the balance 
in caloric intake provided by differences in carbohydrate content. T. foenum-graecum L. “Fenugreek” seeds were 
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purchased from Johnny’s Selected Seeds, Winslow Maine, certified organic for sprouting. Fenugreek seeds were 
ground in the Department of Plant Biology at Rutgers University and hand-delivered to Research Diets Inc., (New 
Brunswick, NJ) for commercial incorporation into treatment diets at 2% of the diet by weight.
Metabolic phenotyping. Assessment of metabolic function is fully detailed in our previous report41. Briefly, 
body composition (fat mass, fat-free/lean mass, and water content) was measured by briefly placing in mice into 
Bruker minispec LF110 time domain NMR analyzer (Bruker Optics, Billerica MA) as described previously41. 
Glucose tolerance was measured using an oral glucose tolerance assay (OGTT) based on repeated sampling of tail 
blood using a glucometer (Ascensia Elite, Bayer, Mishawaka, IN) at 0, 20, 40, 60, and 120 minutes after oral glu-
cose (2 gm/kg) administration. All mice remained in the study for the duration of the 16-week feeding trail, after 
which mice with euthanized following a 8-hr fast by decapitation under deep isoflurane anesthesia. Levels of total 
cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in serum collected at euthanasia were measured 
colorimetrically (Wako Chemicals, Richmond, VA).
16S Metagenomic sequencing. Fecal samples were collected at euthanasia, and DNA preparation, 
sequencing and bioinformatics were performed by the PBRC Genomics Core Facility. DNA was isolated 
using a commercial reagent system (MoBio Power Fecal Kit, MoBio Laboratories, Carlsbad, CA) augmented 
by enzymatic lysis using lysostaphin, mutanolysin, and lysozyme82. Sequencing libraries targeting V4 of the 
gene encoding the 16S ribosomal RNA were generated using a commercially available kit (NEXTflex™ 16S V4 
Amplicon-Seq Library Prep Kit, BIOO Scientific, Austin, TX), relying on 16S gene-specific primer sequences V4F 
5′-GTGCCAGCMGCCGCGGTAA-3′ and V4R 5′-GGACTACHVGGGTWTCTAAT-3′, and including Illumina 
adaptors and molecular barcodes as described by the manufacturer to produce 253 bp amplicons. Samples were 
sequenced with custom primers (BIOO Scientific, Austin, TX) on an Illumina MiSeq instrument using version 
3 sequencing chemistry (300 bp paired end reads). Forward and reverse sequence reads were processed into 
double-stranded DNA contigs using quality control metrics implemented in the software package ‘mothur’83. 
Sequence clustering (at better than 97% identity) to identify operational taxonomical units (OTUs), removal 
of chimeric sequences, and generation of a read count table (i.e. tabulating the occurrence of each OTU in each 
sample) were performed with the software package ‘usearch’84. Taxonomical classification of each OTU sequence 
relied on the SILVA 16S rRNA sequence database version 123.185, and statistical tests for differential representa-
tion were performed with tools incorporated in ‘mothur’, as well as using the software package DESeq. 286. 
Relative abundance of each OTU was examined on the phylum, class, order, family and genus levels.
Statistical analyses. Biochemical data were analyzed using Prism software (GraphPad Software, Inc.), and 
displayed as mean ± standard error, and were analyzed by ANOVA. Statistical significance for all analyses was 
accepted at p < 0.05, and *, **, and *** represent p < 0.05, p < 0.01, and p < 0.001, respectively. Alpha diver-
sity (chao1 metrics) and beta diversity (weighted UniFrac metrics87) were assessed using tools implemented in 
‘mothur’ on the basis of 80,000 sequences per sample. Differential representation of OTUs was assessed using 
DESeq. 2 on the basis of sequence count data, relying on Wald statistics with Benjamini-Hochberg correction 
and a false discovery rate cutoff set at 0.1. Inter-sample relationships relying on Principal Component Analysis 
on the basis of DESeq. 2 output, and data visualizations were both performed using JMP Genomics software 
(SAS, Cary, NC). Pairwise Pearson correlations of individual metrics of metabolic function against individual 
HFD-transformed, fenugreek-corrected OTU expression were carried out using Prism software.
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